Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

SLXP 140.42 +4.86 (3.59%)
price chart
Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. (SLXP) are up 3.71% to $156.70 in pre-market trade after it was reported that the company is in talks to sell itself to Actavis Plc, (ACT) , sources told Bloomberg, after it failed to reach a ...
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) to Ring The Nasdaq Stock Market ...  GlobeNewswire (press release)
Salix Pharmaceuticals Backs Out Of Cosmo Merger  ValueWalk
Related articles »  
A Bizarre Pharma Love Triangle
Salix Pharmaceuticals is a specialty pharma company that specializes in gastroenterology treatments. In the article, I mentioned Salix Pharmaceuticals was being discussed as a prime candidate to do a tax-inversion deal. Just a few days later on July ...
Salix Said in Talks to Sell to Actavis as Allergan Fades  Bloomberg
Proxy Firm ISS Urges Shareholder Vote at Allergan  Wall Street Journal
Related articles »  
Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call ...
RALEIGH, N.C., Oct 23, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. SLXP, -1.49% today announced that the Company will report third quarter 2014 financial results following the close of the U.S.
Stocks in the News � Atmel, (NASDAQ:ATML), Salix Pharmaceuticals, (NASDAQ ...  Techsonian (press release)
Related articles »  
Salix's Xifaxan Sales Expected To Go Downhill
Sales of Salix Pharmaceuticals, Ltd.'s (SLXP) drug Xifaxan face the risk of decline due to availability of new all-oral drugs for treatment of the hepatitis C virus (HCV), according to physician survey along with research conducted by Credit Suisse ...
Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) received a price target increase from $155 to $185 by Stifel, which maintained a Buy rating.
Salix Pharmaceuticals Price Target Raised to $185.00 (SLXP)  Ticker Report
Stifel Nicolaus Increases Salix Pharmaceuticals Price Target to $185.00 (SLXP)  Watch List News (press release)
Related articles »  
Notable Movers -Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP ), USG Corporation ...
Stamford, Connecticut - October 24, 2014- (Techsonian) - Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP ) declared that the Company will report third quarter 2014 financial results following the close of the U.S.
EC approves ulcerative colitis med
The European Commission approves privately-held Switzerland-based Ferring Pharmaceuticals' Cortiment (budesonide) for the induction of remission in patients with active mild-to-moderate ulcerative colitis.
Ferring Pharmaceuticals: CORTIMENT � MMX� , a new treatment for ulcerative ...  Business Wire (press release)
Related articles »  
Sell Side's Views On Salix-Actavis Potential Merger
Allergan, in a desperate attempt to fend off Valeant's bid, revived acquisition talks with another pharmaceutical company, Salix Pharmaceuticals, Ltd. (SLXP), in September. Allergan believes that acquisition of Salix would make Allergan a complex and ...
Salix: The Field of Potential Buyers is Vast, Analyst Says  Wall Street Journal (blog)
Exclusive: Actavis plans new merger approach for Allergan - sources  Reuters
Related articles »  
RSI Alert: Salix Pharmaceuticals (SLXP) Now Oversold
In trading on Monday, shares of Salix Pharmaceuticals Ltd (NASD: SLXP) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $135.60 per share.
Related articles »  
Pharma Stocks in the News: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) said it has received final Food and Drug Administration approval for its Uceris rectal foam product to induce remission in patients with active mild-to-moderate distal ulcerative colitis.
Related articles »